Fundraising FoxvenBio Partners — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.
BiotechBerkeley, US
Allison J. Hulme(CEO & President)inJohn Kincaid(Chief Scientific Officer)inDavis Ryman(Executive Officer)inMicah Zajic(Executive Officer)inIan Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)
Board seatRichard Gaster· per SEC Form D
Co-investorsCoastCapCTI Life Sciences Fund L.P.Felix JahnFJ LabsLuma GroupSofinnova Ventures+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.